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Abstract
The molecular pathogenesis of primary mielofibrosis (PMF) is still largely unknown. Recently, single-nucleotide
polymorphism arrays (SNP-A) allowed for genome-wide profiling of copy-number alterations and acquired uniparental
disomy (aUPD) at high-resolution. In this study we analyzed 20 PMF patients using the Genome-Wide Human SNP Array 6.0
in order to identify novel recurrent genomic abnormalities. We observed a complex karyotype in all cases, detecting all the
previously reported lesions (del(5q), del(20q), del(13q), +8, aUPD at 9p24 and abnormalities on chromosome 1). In addition,
we identified several novel cryptic lesions. In particular, we found a recurrent alteration involving cytoband 20p13 in 55% of
patients. We defined a minimal affected region (MAR), an amplification of 9,911 base-pair (bp) overlapping the SIRPB1 gene
locus. Noteworthy, by extending the analysis to the adjacent areas, the cytoband was overall affected in 95% of cases.
Remarkably, these results were confirmed by real-time PCR and validated in silico in a large independent series of
myeloproliferative diseases. Finally, by immunohistochemistry we found that SIRPB1 was over-expressed in the bone
marrow of PMF patients carrying 20p13 amplification. In conclusion, we identified a novel highly recurrent genomic lesion
in PMF patients, which definitely warrant further functional and clinical characterization.
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Introduction
Primary myelofibrosis (PMF) is a chronic myeloproliferative
neoplasm (MPN) in which the clonal transformation of the
hematopoietic stem cell (HSC) results in the prominent expansion
of megakaryocytes and granulocytes in the bone marrow (BM) [1].
In its full-blown stage, PMF is associated with the progressive
deposition of extracellular matrix components in the BM
parenchyma configuring the picture of myelofibrosis (MF), which
results from the persistent stimulation of BM mesenchymal
components by myeloid clone-derived growth factors and
cytokines [2,3]. Such a perturbation of the BM homeostasis may
be profound in the advanced phases of the disease and eventually
results in the occurrence of extramedullary haematopoiesis
consequent to a defective HSC BM niche [1]. Similar dynamics
of BM stroma disarrangement may sustain the development of MF
during the natural course of MPNs other than PMF, such as
polycythemia vera, and these cases, accounting for around 25% of
MF cases, are accordingly defined secondary myelofibrosis (SMF)
[4].
The molecular pathogenesis of PMF is largely unknown, though
a number of genomic abnormalities have been associated to this
disease. In particular, different point mutations involving Janus
kinase 2 (JAK2), Myeloproliferative Leukemia Virus (MPL), TET
oncogene family member 2 (TET2), Sex Combs-Like 1 (ASXL1),
Casitas B-lineage lymphoma proto-oncogene (CBL), and IKAROS
family zinc finger 1 (IKZF1) have been recently described in MPNs
and also in PMF [5]. Of note, mutations occurring at JAK2 locus
on 9p24 chromosome appear to play a pivotal role in PMF and
currently represent a major criterion for diagnosis according to the
World Health Organization [1]. However, none of these
mutations is specific for PMF being recorded in different MPNs.
Interestingly, they were found to be not mutually exclusive nor
could be traced back to a common ancestral clone, highlighting a
certain degree of heterogeneity in MF genetics. To this regard, the
intriguing possibility of independently emerging multiple abnor-
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myeloproliferation) has been even recently raised [5].
At chromosomal level, metaphase cytogenetics (MC) detects an
abnormal karyotype of PMF in about 34% of cases at diagnosis,
the most frequent lesions being del(20q), del(13q) and abnormal-
ities of chromosome 1 [6]. Additional observed alterations
included +8, +9, abnormalities of chromosomes 3, 25/del(5q),
27/del7(q), del(12p) and +21. However there’s a wide heteroge-
neity among patients and specific recurrent patterns have not been
identified so far [7]. However, it should be noted that the
resolution of conventional karyotyping, or G-banding, is only 3–
20 Mb. Conversely, new DNA array–based methods, such as SNP
arrays (SNP-A), increased the resolution up to the base-pair (bp)
scale, enabling studies of copy number variants (CNVs) and
acquired Uniparental Disomy (aUPD). CNVs are amplified or
deleted regions ranging in size from intermediate (1–50 kb) to
large (50 kb–3 Mb) [8–10] and are recognized as a major source
of human genome variability. Importantly, change in copy
number (CN) is involved in cancer formation and can increase
during tumor progression, influencing phenotypes and prognosis
[11–13]. aUPDs are regions of loss of heterozygosity (LOH) that
occurs without concurrent changes in the gene copy number,
phenomenon also reported as copy-neutral LOH. These defects
are attributed to errors of mitotic recombination in somatic cells
and are being increasingly recognized in a variety of neoplasms
[14,15]. Importantly, high-resolution SNP-A can be easily applied
in karyotype analysis representing the possible starting point in
discovery several pathogenetically relevant alterations. In fact, it
does not depend upon the availability of live, dividing cells, and
consequently can yield results when routine MC is not
informative. Moreover, due to its higher resolution as compared
with MC, smaller, otherwise uncovered deletions and duplications
can be visualised.
In the field of MPN, SNP-A profiling studies recently
highlighted the impact of this new methodology for detecting
regions of aUPD, identifying commonly altered regions and
suggesting novel target genes [13,16,17]. However, all these
studies have been conducted on cohorts of patients affected by
MPNs in general and no study has so far focused on PMF.
In this study we performed high resolution karyotyping of a
cohort of 20 patients affected by PMF using the most recent
Affymetrix SNP-A (Genome-Wide Human SNP Array 6.0).
Specifically, we studied DNA from tumour samples and normal
matched DNA from the same PMF patients, as well as DNA from
healthy individuals aiming to identify novel cryptic aberrations.
Methods
Patients
We studied 20 PMF patients diagnosed according to WHO
criteria [1]. For each patient peripheral blood (PB) sample, bone
marrow (BM) aspirate and BM trephine biopsy were collected at
diagnosis. Due to the scant material obtained from BM aspirates
(often resulting in a dry tap), SNP-A karyotyping was carried out
on PB samples. Conversely, conventional metaphase cytogenetic
analysis was performed on bone marrow in the only two cases in
which an adequate amount material was collected.
The cases were equally divided into a training set (10 PMF) and
a test set (10 PMF). The main clinical features were homoge-
neously represented in the two groups (Table S1). In particular,
the patients of the training test and test set reported a median age
of 68 and 74 years, a female/male ratio of 50% and 40%, a
median follow up of 28,5 and 38,5 months and a leukemic
transformation of 0% and 2%, respectively. JAK2 mutational
status was assessed in all cases as previously described [18] (for
details see File S1). Ten patients (6 in the training and 4 in the test
set) presented with JAK2 mutations.
In both training and test set the genomic DNA was isolated
from peripheral blood myeloid cells. Additionally, in the training
set we also studied non neoplastic T-lymphocytes isolated from PB
(see below). Moreover, genomic DNA collected from 10 healthy
individuals served as further control.
All the study was approved by the local ethical committee
(Department Sera `gnoli and San Salvatore Hospital Review
Boards) and written permission and informed consent have been
obtained from all patients before sample collection.
Purification of myeloid and CD3
+ cells from peripheral
blood
Peripheral blood mononuclear cells (PBMC) and granulocytes
were obtained from 20 patients by Ficoll-Paque by density
gradient separation (GE Healthcare Wisconsin, USA). Subse-
quently, in 10 cases (training set), we collected granulocytes,
representing the clonal population, on one hand, and the PBMC
on the other. The latter were then processed in order to isolate
bona fide non neoplastic T-lymphocytes. CD3
+ cells isolation was
performed by immunomagnetic labelling of CD3
+ cells followed
by a separation process using the MACS device (Milteniy Biotech,
Bergisch Gladbach, Germany). In brief, up to 2610
8 PBMNC
were washed with PBS and 1% human albumin to reduce the
labeling volume to 10 ml. The cells were then incubated with a
clinical grade anti-CD3 monoclonal antibody (MoAb) conjugated
to microbeads (MACS CD3 reagent, Myiltenyi Biotech) for
20 minutes. After washing, CD3
+cells were purified on a MS
column (Miltenyi Biotech). After selection, cells present in the
positive (CD3) and negative (PBMNC) fractions were counted and
submitted to flow cytometry analysis. Assessment of CD3
+ cells
before and after the separation process was carried out by labeling
of the target cells with anti-CD3-phycoerythrin (PE) MoAb
(Becton Dickinson, San Jose, CA, USA), followed by cytometric
reanalysis of purified cells performed on a gated population set on
scatter properties by FACScan equipment (Becton Dickinson). A
minimum of 10,000 events was collected in list mode on FACScan
software.
In the other 10 cases (test set), conversely, only granulocytes
were collected and used for the subsequent analyses (test set).
Notably, to ensure the collection of adequate neoplastic
components, a morphological evaluation of the granulocytic
fractions was performed on smears obtained after cytospin
enrichment. Actually, the granulocytic fraction usually included
a variable proportion of immature myeloid cells, consistently with
the diagnosis of PMF. Only samples for which at least 80% of the
cellular population was constituted by myeloid elements were
selected for the following analysis.
SNP Array assay
Genomic DNA was extracted using QIAamp DNA Mini Kit
(QIAGEN Inc., Valencia,. CA, U.S.A.) Concentration and quality
samples were quantified by Nanodrop ND-1000 spectrophotom-
eter running software version 3.0.1 (NanoDrop Technologies, Inc.,
Rockland DE). DNA was then treated as far manufacturer’s
instructions (Affymetrix, Santa Clara, CA, USA) and finally
hybridized to the Genome-Wide SNP array 6.0 (Affymetrix, Santa
Clara, CA, USA).This array contains 906,600 Single Nucleotide
Polymorphism (SNP) probes and more than 945,826 copy number
variant (CNV) probes, providing marker spacing in the range of as
low as 700 bases. Briefly, 500 ng of highly purified genomic DNA
from each patient was processed in each step by a provided
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6. and other prescribed kits. First DNA was cut by restriction
enzymes NspI and StyI (Nsp I Enzyme, Sty I Enzyme by New
England Biolabs) followed by adaptor ligation (T4 DNA Ligase by
New England Biolabs). A generic primer that recognizes the
adaptor sequence was used to amplify adaptor-ligated DNA
fragments (TITANIUM DNA Amplification Kit by Clontech).
PCR conditions have been optimized to preferentially amplify
fragments in the 200 to 1,100 bp size range. PCR products were
then purified (Magnetic Beads by Agencourt) fragmented and
labeled with a fluorochrome. After washing, the arrays were
incubated with a streptavidin-phycoerythrin conjugate to enable
detection of hybridized fragments on the array. The fragment
binding (which reflects the genotype) was then measured by a
scanner picking up the fluorescent signals on the array feature
scanned (GeneChipH 3000 Scanner with 7G upgrade Affymetrix,
Santa Clara, CA, USA).
Data Analysis
Data were analysed using the Affymetrix Genotyping Console
(GTC) 4.0 and Partek Genomic Suite 6.5. First, we uploaded on
GTC 4.0 all sample attribute (ARR) and intensity data (CEL) files.
All the arrays passed the recommended Quality Control (QC)
threshold ($0.4) according to manual instruction (GTC 4.0
manual, Affymetrix, Santa Clara, CA, USA). Thus, we generated
CHP files by performing genotyping analysis, based on Birdseed
v.2 algorithm and using default parameters.
Subsequently, all CEL and CHP files were uploaded on Partek
Genomic suite 6.5. We updated all the arrays to the new human
genome build Genome Reference Consortium GRCh37 (ucsc
hg19), corrected the GC waviness and used only the latest builds of
databases (Refseq, Database of Genomic Variants).
We then performed a paired analysis of the 10 samples,
constituting the training set, for which matched normal DNA was
available. In particular, we detected amplifications and deletions
using Partek genomic segmentation algorithm (10 minimum
genomic markers and a p-value threshold #0.001.). Subsequently,
we performed an unpaired analysis of the 10 cases, constituting the
test set. Specifically, we compared the tumor DNA to an
homemade reference baseline (made up by DNA from 10 healthy
individuals). The latter was preferred to Partek baseline, basing on
its consistency with the paired training test results (for details see
file S1).
In all copy number analyses we excluded from the study the
chromosomes X, Y, the mitochondrion, all the regions with low
density markers and finally the CNV segment ,1 Kb and UPDs
regions ,1 Mb. After that, in order to evaluate the prevalence of
CNVs within each chromosome we normalized the number of
alterations on chromosome length (in Mb).
For further details on SNP-A analysis see file S1.
TaqMan Copy Number assay
To validate target genomic copy number amplification found by
SNP-A analysis, we used a TaqMan Copy Number assay (Applied
Biosystems; Foster City, CA). In particular, the target copy
number was assessed with a specific TaqMan Copy Number Assay
(Hs04039030_cn; Applied Biosystems; Foster City, CA) and
TaqMan Copy Number Reference Assay RNase P (Applied
Biosystems). For each sample 4 repeats of 20 ng of DNA were
run in a duplex real-time Polymerase Chain Reaction with
TaqMan Universal Genotyping Master Mix, a FAMH dye-labeled
TaqManH Copy Number Assay and a VICH dye-labeled
TaqManH Copy Number Reference Assay (Applied Biosystems;
Foster City, CA). The RNaseP reference genes are known to be
present in two copies in a diploid genome, regardless of the copy
number of the target of interest, and are used to normalize sample
input and minimize the variation between the target of the test and
reference assay.
The reactions were performed on the genomic DNA from the
original tumour samples and, according to the manufacturer’s
protocol, were run on an ABI 7900HT real-time PCR machine
(Applied Biosystems; Foster City, CA) and primarily analyzed by
SDS Software 2.3.
The relative quantitation analysis, without calibrator sample,
was then performed by CopyCaller
TM Software v1.0
In silico validation
To confirm our results in a validation set, we examined two data
sets of Affymetrix CEL files publicly accessible in the GEO
database (http://www.ncbi.nlm.nih.gov/geo/). Since there were
no available series composed exclusively of PMF cases, all the
available MPN cases were included in the validation set. In
particular, we analysed raw data from 7 patients with PMF blast
phase’’originally studied by GeneChipH Human Mapping 250K
Nsp, and from 39 MPN patients previously analysed by Affymetrix
Human Mapping 50K Array Xba 240 (GSE19647) [13].
Moreover, included the raw data from 14 patients affected by
MDS/MPN, originally analysed by using our same array
(Genome-Wide SNP array 6.0) (GSE21991) [19].
Immunohistochemical validation
In order to evaluate the expression of SIRPB1 protein, we
studied by immunohistochemistry selected cases carrying or not
the amplification within the 20p13 cytoband (containing the
SIRPB1 gene locus). Immunohistochemistry was performed as
previously reported, on bone marrow trephine biopsies obtained
from the posterior iliac crest [3]. Briefly, Four-micrometers-thick
sections of bone marrow biopsies were deparaffinized and
rehydrated to water, subsequently the slides were microwave
treated in Tris-HCl/EDTA buffer pH 9.0 (DakoCytomation) for a
total of 20 minutes prior to PBS washing. After neutralization of
the endogenous peroxidase with H2O2 for 10 minutes, the sections
were first incubated with protein block (Novocastra, UK) for
10 minutes. Sections were then incubated with the primary
polyclonal antibody rabbit anti-human SIRPB1 (Proteintech
Group, USA; dilution 1:50). Incubation time was overnight at
4uC. Normal rabbit serum was used instead of primary antibodies
as negative control. Binding of the primary antibody was revealed
by a polymer detection system (Novolink max polymer detection
system, Novocastra,UK) using DAB (3,39-Diaminobenzidine,
Novocastra,UK) substrate-chromogen. After counterstaining with
hematoxylin (Novocastra,UK), the sections were analysed under a
Leica DM2000 optical microscope (Leica, Germany) and captions
were collected using a Leica DFC320 digital camera (Leica).
Results
Identification of CNV, LOH and aUPD
First, we aimed to detect unbalanced chromosomal defects as
well as aUPD. To address this issue we analysed cases included in
the training set (10 cases), and performed a paired analysis for CN
determination by genome wide SNP array 6.0. Specifically, we
directly compared normal (T lymphocytes) and neoplastic
(myeloid cells) matched samples. We identified a total of 2,765
CNVs, ranging in size from 1 kb to 23 Mb (Figure 1) (File S1). In
particular, the CNVs were represented by amplifications
(N=1,584, median size 14,5 Kb - range of 1 Kb–2,3 Mb),
deletions (N=1,132, median size 16,7 Kb - range of 1 kb–
A Novel Recurrent Alteration in Myelofibrosis
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7,2 Mb)(Figure 2). Based on the most updated Genomic Toronto
Database version (http://projects.tcag.ca/variation/), 1,773
CNVs (64%) of detected CNVs were then regarded as known,
while 992 CNVs (36%) were considered as novel.
We then looked at the CNVs distribution across the chromo-
somes in order to assess whether specific chromosomes were
predominantly affected. After opportune normalization on
chromosome size, we observed that the number of CNVs was
over the median value in the chromosomes 4, 7, 8, 9, 10, 11, 14,
16, 20 and 22, while it was below in the remaining ones. However
the difference was not significant (x
2, pvalue=0,99)(Figure 3).
As far as the single cases were concerned, we identified a mean
of 343 CNVs/patient (range 188–602), with a mean size of
168,623 kb and a median size of 15,912 kb. Amplifications were
confirmed to be the commonest lesions among patients, though all
the types of abnormalities were detected in most instances (Figure
S1).
Subsequently, we investigated whether the above CNVs were
present in the test set (N=10 cases) as well. To do this, we first
compared the 10 cases of the test set with the DNA obtained from
the healthy donors and identified 419 cytobands that were altered.
Subsequently, we compared them with the 744 cytobands found to
be affected in the training set. Indeed, a significant overlap was
recorded between the two groups; specifically, in the test set we
confirmed 327/744 lesions (44%)(p=0.0053)(Figure S2A–B).
Importantly, as internal control, we confirmed the presence of
the two abnormalities previously detected by MC: a trisomy 8 and
a 5q deletion (Figure 4A–B).
We investigated whether we could identify the lesions detected
in the previously published SNP-A profiling studies, which had
been performed at a lower resolution. Actually, we identified the
presence of different regions of aUPD on chr9 at JAK2 locus, on
chr 13q, on chr 1 and on chr 11. More specifically, concerning the
JAK2 locus, we found 5 amplifications, 1 deletion and 1 aUPD in
cases carrying JAK2 somatic mutations (as detected by PCR and
direct sequencing), while 1 amplification, 1 deletion and 1 aUPD
were recorded in unmutated cases. In addition, we detected in 2/
20 patients and in 3/20 patients respectively, two large region of
aUPDs in correspondence to the MPL and CBL genes. Further
validation by direct sequencing was not possible due to the lack of
residual material. (Figure S3A-B-C).
PMF presents with recurrent abnormalities on 20p13
We then looked for CNVs consistently recurrent in our dataset.
First the analysis was carried out in the training set (10 cases). As
the matched control was represented by T-lymphocytes, we
excluded CNVs on chromosomes 7p34, 7p14.1, 14q11.2 (recur-
Figure 1. Karyoview of training set. Amplification with LOH (Light blue), Amplification without LOH (Dark blue), Copy Neutral LOH (aUPD, Green),
Deletion with LOH (Violet), and Deletion without LOH (Cyclamen) are represented. All the 2,765 lesions recorded in the training set are depicted.
doi:10.1371/journal.pone.0027560.g001
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physiological alteration secondary to T-cell receptor editing
process.
No lesion was found to be present in up to 6/10 cases.
Conversely, we found 1 CNV in 5/10 samples, 5 in 4/10 samples,
47 in 3/10 and 285 in at least 2/10 (Figure S4).
Specifically, the most common recurrent lesion was an
amplification occurring in 1p31.1 cytoband. However, as this
was an already known lesion involving the chromosome 1 [20], we
focused on CNVs occurring in 4/10 cases and evaluated them in
the test set. These genomic imbalances, in particular, involved the
cytobands 1p31.1, 10q23.31, 4q25, 4q31.3 and 20p13. By looking
for these lesions in the test set, we found the 20p13 amplification to
be the most frequently occurring one (7/10 cases). Such
amplification within the 20p13 region was thus overall recorded
in 11 out of 20 cases (55%). Subsequently, due to the high
prevalence of the lesion and the known involvement of
chromosome 20 in myeloid malignancies [21–23], we further
extended our focus to the entire 20p13 cytoband. In particular, 9/
10 patients in the training set showed different alterations affecting
the cytoband 20p13. We then tested the presence of 20p13
abnormalities in the test set too, and we found it in 10/10 cases.
Thus, overall, 19/20 patients showed abnormalities on chromo-
some 20p13.
Finally, in order to assess the prevalence of 20p13 abnormalities
in an independent panel of cases, we tested an in silico validation set
including 14 cases of MDS/MPN, 7 cases of PMF in blast phase
and 39 previously-reported MPN cases for which high SNP
karyotiping CEL files were available (http://www.ncbi.nml.nih.
gov/projects/geo/) [13,19]. We could confirm the presence of
lesions affecting the 20p13 cytoband in 7/14 MDS/MPN patients,
5/7 PMF blast phase patients, and in 1/39 MPN patient (Figure
S5).
Importantly, among all the 20p13 lesions occurring in our PMF
patients, the amplification reported in 11/20 patients identified a
minimally affected region (MAR). Specifically the MAR was a
segment of DNA amplified 4 times (average copy number=4,1)
on chromosome 20, extending for about 9,911 bps from 1572019
to 1581930 nucleotides and overlapping the SIRPB1 gene locus
(Figure 5).
TaqMan Copy Number assay of MAR
In order to validate the results obtained with the SNP-A, we
used the TaqMan Copy Number Assay using a specific probe
overlapping under the CNV of interest on 20p13 cytoband
(Hs04039030_cn; Applied Biosystems; Foster City, CA). We
studied 10 samples, in which the MAR appeared to be involved
at SNP-A analysis, and for which residual DNA was available.
Furthermore, we analyzed 6 additional DNA samples,
including 1 negative control as well as DNA from matched
non neoplastic T lymphocytes of 5/10 patients. We also tested
the target copy number amplification on a human genomic
DNA control (Reference Genomic DNA, 103, Affymetrix,
Santa Clara, CA, USA). The analysis was performed in
quadruplicate and three times in three different days for
further control.
High inter-assay and intra-assay reproducibility was recorded.
In particular, analogue results were obtained in the replicates and
consistent results were found within each repetition with a sDCt
below 0,15. Overall, the assay confirmed the SNP-A results, with a
consistency of 70%. Specifically, we detected the target copy
number to be amplified in 7/10 patients (Figure 6).
SIRPB1 protein detection
Following the detection of a 20p13 amplification overlapping
the SIRPB1 gene, we tested the expression of SIRPB1 protein by
immunohistochemistry on 5 PMF cases characterized by 20p13
amplification and on 5 PMF cases not showing the molecular
abnormality. Interestingly, we found a different expression of
SIRPB1 between the two groups (Figure 7). In particular, the
protein was widely expressed in all myeloid lineages, including
megakaryocytes, macrophages, dendritic cells, and myeloid
precursors in cases with SIRPB1 amplification. On the contrary,
it was essentially restricted to macrophages and dendritic cells in
PMF cases not carrying 20p13 abnormalities (Figure 7). Of note,
in cases characterized by 20p13 amplification, SIRPB1 expression
showed a combined intracytoplasmatic and membranous pattern,
while it was mainly bound to the membranes in the other cases
(Figure 7).
Discussion
In this study, we aimed to identify novel cytogenetic
abnormalities in PMF patients by using high-density SNP-A.
Previous studies showed the ability of such technique in detecting
novel genetic lesions in both myeloid and lymphoid disorders [24–
26]. In particular, SNP-A profiling retains several advantages if
compared to metaphase cytogenetic (MC), including the ability to
detect lesions even when cells are not actively dividing, a condition
favourable to the investigation of chronic myeloid neoplasms
(CMN), and definitely higher sensitivity and capacity to detect
aUPD. Noteworthy, the latter two features also distinguish SNP-A
analysis from CGH. On the other hand, a major limitation of
SNP-A, in comparison to MC, is its inability to recognize
chromosomal translocations [27].
Figure 2. Global distribution of CNVs across PMF genomes. All
the CNVs with relative frequencies are reported: amplifications (both
with and without LOH) in blue, acquired uniparental disomy regions
(aUPD) in green and deletions (both with and without LOH) in red.
doi:10.1371/journal.pone.0027560.g002
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number of lesions (2,765 CNVs) including aUPD, deletion and
amplification, many of which (992/2,765; 36%) turned out to be
previously uncovered. Notably, according to our study design, all
copy number changes detected by SNP-A paired analysis in the
training set, were then validated in a test set. Specifically, the
correspondence between the two groups was significant (p=
0.0053), with 44% of lesions confirmed in both (Figure S2).
Concerning the lesions previously associated with MPN, we
identified del(13q), del(20q), and abnormalities on chromosome 1,
+9 +8 and del(5q). Actually, we identified the presence of different
regions of aUPD on chr9 at JAK2 locus [16], on chr 13q, on chr 1
and on chr 11 [17,28].
In particular, we observed large regions of aUPDs in
correspondence to the MPL, CBL and RB1 genes which are
commonly mutated or deleted in PMF.
Figure 4. Correspondence between metaphase cytogenetic and SNPs-A karyotyping. A) Trisomy of chromosome 8 identified in one
patient (yellow bar) known to carry the same abnormality basing on metaphase cytogenetic results. Please note two different cases randomly
selected and presented as negative controls (arrows). B) Deletion of chromosome 5q identified in one patient (light blue bar) known to carry the
same abnormality basing on metaphase cytogenetic results. Please note two different cases randomly selected and presented as negative controls
(arrows).
doi:10.1371/journal.pone.0027560.g004
Figure 3. CNVs distribution across chromosomes. On the x axis all the chromosomes except x, y, and mitochondrion are presented. On the y
axis the number of CNVs affecting each chromosome after opportune normalization on chromosome size, is reported. The dotted line represents the
median value of CNV per chromosome.
doi:10.1371/journal.pone.0027560.g003
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lesions previously detected by MC in our cohort (namely del(5q)
and trisomy 8). Thus, SPN-A karyotyping was confirmed to be an
effective tool for the identification of both cryptic and larger
genomic abnormalities [5,29]. Taken together, our results
confirmed the presence of a complex and heterogeneous karyotype
in PMF patients, basically consistent with previous studies [7] and
proposed novel CNVs for further characterisation.
As far as newly identified aberrations were concerned, we
focused on the lesions which recurred at higher frequency in our
series, thus being candidate to retain a potential pathogenic
significance. Interestingly, as indicated by other studies using less
sensitive techniques [30], PMF was confirmed to have heteroge-
neous lesions at cytogenetic level. Actually, all patients presented
with a complex karyotype, with a minimum number of CNV/
patient of 188. Remarkably, however, when a paired analysis was
performed in the training set, no lesion was consistently present in
all the cases, not even in up to 60% of them. On the other hand, a
few new lesions were found in 50% of patients. Among them, we
focused on an amplification affecting the cytoband 20p13, since it
proved to be the most frequent in the entire series (training + test
set), the overall prevalence of such CNV being 55%. Noteworthy,
if confirmed in larger series and functionally relevant, it would
represent the commonest genomic lesion so far described in PMF,
together with JAK2 somatic mutations.
To better understand the context of this lesion we primarily
extend our attention to the adjacent areas, in the 20p13 cytoband.
Interestingly, we found that all the patients except one (19/20),
have at least one alteration (amplification, deletion or aUPD)
occurring in the 20p13 cytoband. Subsequently, we assessed the
prevalence of 20p13 abnormalities in an independent validation
data set. Specifically, we studied a group of 60 myeloid tumours,
basing on previously published data which were available online.
Remarkably, we confirmed the presence of lesions affecting 20p13
cytoband in 7/14 MDS/MPN patients, 5/7 PMF patients and 1/
39 MPN patient. Of note, this finding was then consistent with the
concept that different myeloid malignancies may share common
genetic abnormalities [31,32]. In this regard, 20p13 gains were
recently described in MDS [22], though occurring at very low
frequency. Nevertheless, other loci on chromosome 20 have been
found to be involved in myeloid malignancies, though the
implicated genes and the exact consequences are poorly known
[21,23].
Importantly, among all the 20p13 lesions detected in our PMF
patients, we could define the CNV occurring with 55% of
frequency as a minimally affected region (MAR). In particular the
MAR is an amplification spanning over 9,911 bps, in correspon-
dence to the SIRPB1 gene locus.
Subsequently, we investigated whether the copy number
amplification within the SIRPB1 gene could be eventually reflected
Figure 5. Minimally affected region (MAR) definition. Genomes from all patients are represented as single rows. MAR (black arrow) was
defined as the minimal DNA fragment affected by any imbalance in the majority of cases. Correspondence to SIRPB1 gene was found (red arrow).
Please note the occurrence of other abnormalities rather than amplification within the MAR or in the adjacent area in some cases.
doi:10.1371/journal.pone.0027560.g005
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27560at protein level. SIRPB1 is a member of the signal-regulatory-
protein (SIRP) family, belonging to the immunoglobulin super-
family. SIRPB1 is expressed in neurons and a limited subset of
hematopoietc cells mainly consisting of macrophages and dendritic
cells (DCs) [33–36]. Importantly, the efficient cell-surface
expression of SIRPB1 requires the association with DAP12, a
dimeric adaptor ITAM- bearing protein, located in the plasma-
membrane. Upon stimulation, the SIRPB1/DAP12 complex
induces tyrosine phosphorylation of a number of kinases including
the mitogen-activated protein kinases (MAPKs), ERK1, and
ERK2. In addition, it binds the tyrosine kinase SYK, leading to
the activation of the SYK-JAK-STAT intracellular cascade [37–
40].
To date no involvment of SIRPB1 protein has been reported in
any diseases, except for the Alzheimer’s disease where its up
regulation is responsible to increase the phagocytosis process [41].
However, 20p13 abnormalities (amplifications, deletions or
translocations) have been reported in sporadic cases of osteosar-
coma, adenocarcinoma, Adult T-cell lymphoma/leukemia
(HTLV-1+), and chronic myeloid leukemia according to the
Cancer Chromosome database (http://www.ncbi.nlm.nih.gov/
cancerchromosomes).
Indeed, in our series we found SIRPB1 significantly more
expressed in patients carrying the genomic abnormality rather
than in the other cases. Specifically, in patients not harboring the
20p13 amplification, we found, as attended, a sporadic expression
of SIRPB1 mainly restricted to dendritic cells (DCs) and
macrophages. Conversely, in patients carrying the 20p13 alter-
ation, we appreciated an intense expression of SIRPB1 in all
myeloid cells, this reflecting the occurrence of the lesion in a
common myeloid progenitor. Furthermore, of note, in case of
20p13 amplification SIRPB1 expression was not limited to the
plasma-membrane, but was extended to the cytoplasm as well. It is
conceivable that this phenomenon reflected the complete
saturation of the SIRPB1 binding sites on the plasma-membrane
leading to an abnormal accumulation in the cytoplasm. Bearing in
mind the involvement of SIRPB1 in SYK-JAK-STAT signalling, it
is possible that a deregulated SIRPB1 expression and/or function
might eventually sustain proliferation and survival of affected cells.
Intriguingly it may represent an alternative stimulation in JAK2
wt
cases, possibly having an additive/synergistic effect in JAK2
mut
ones. In this regard, the two lesions did not appear to be mutually
exclusive, as 20p13 amplification was recorded in both JAK2
wt
and JAK2
mut patients.
Figure 6. Validation of MAR abnormalities TaqMan Copy Number Assay. Each column represents a single genome (P=patient; C=control).
Bars correspond to standard deviations. On the y axis, detected copy number values are presented. C1=gDNA from Affymetrix; C2=healthy donor;
C3–C7=patients matched DNA from non neoplastic cells; P1–P10=patients.
doi:10.1371/journal.pone.0027560.g006
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27560In conclusion, we detected a novel recurrent lesion involving
20p13 and SIRPB1 gene in PMF patients. Future studies are
definitely warranted in order to further characterize the genomic
lesion and its functional consequences, as well as to assess the
possible clinical relevance of such lesion.
Supporting Information
Figure S1 Distribution of CNVs across patients. On the
y-axis, the CNV number for each patient is presented.
Amplifications (both with and without LOH) in blue, acquired
uniparental disomy regions (aUPD) in green and deletions (both
with and without LOH) in red.
(TIF)
Figure S2 CNVs recorded in the test set. A) Karyoview of
test set: Amplification with LOH (Light blue), Amplification
without LOH (Dark blue), Copy Neutral LOH (aUPD, Green),
Deletion with LOH (Violet), and Deletion without LOH
(Cyclamen) are represented. All the 2,096 lesions recorded in the
test set are depicted. B) Venn-Diagram representing the significant
overlap between the cytobands recognised as affected by any
imbalance in the training (violet) and test (blue) set, respectively
(p=0.0053).
(TIF)
Figure S3 Acquired uniparental disomy (aUPD) in PMF
patients. Amplification with LOH (Light blue), Amplification
without LOH (Dark blue), Copy Neutral LOH (aUPD, Green),
Deletion with LOH (Violet), and Deletion without LOH
(Cyclamen) are represented. Please note each row represents a
single patient and in particular empty rows represent different
cases randomly selected as negative controls. A) Three patients
reported aUPD regions (green bars) in correspondence to the
CBL gene. B) Three patients presented aUPD regions (green
bars), one patient reported a deletion with LOH (violet bar) one
patient showed a deletion without LOH (cyclamen bar) and two
patients presented a micro amplification without LOH (blue
bars): all these alterations overlapped the RB1 gene. C) Two
patients reported aUPD regions (green bars) in correspondence to
the MPL gene.
(TIF)
Figure S4 Recurrence of CNVs across PMF patients. On
the x-axis, the number of patients (evaluated in the training set) is
presented. On the y-axis, the number of CNVs recurring in a
certain number of patients is offered.
(TIF)
Figure S5 Recurrence of 20p13 in a panel of myelo-
proliferative neoplasms. Basing on in silico analysis, 20p13
abnormalities were recorded in a significant proportion of MPN
cases. On the x-axis, three different datasets are reported, based on
different microarray technology (Affymetrix SNPs-array 6.0,
Affymetrix Human Mapping 250K Nsp, and Affymetrix Human
Mapping 50K Array Xba 240, respectively).
(TIF)
File S1 All the 2,765 CNVs detected in the training set
patients are reported. For each lesion is indicated the
length, the chromosome , the cytoband and the genes
eventually involved.
(XLS)
Table S1 Patients Characterisctics.
(DOC)
Figure 7. Immunhistochemical expression of SIRPB1. A–B) In PMF cases not showing 20p13 amplification, SIRPB1 expression is mainly
confined to BM macrophages and dendritic cells (B, green arrows) and to scattered myeloid cells (B, red arrows). C–D) By contrast, in cases with 20p13
amplification, SIRPB1 is diffusely expressed by myeloid and megakaryocytic elements with a combined cytoplasmatic and surface expression (D, inset,
red arrows). Images are relative to two representative cases out of ten tested (5 per condition). Anti-SIRPB1 immunostaining with the Strept-ABC
method and DAB chromogen (brown signal). Original magnifications: a, c 6200; b, d, inset 6400.
doi:10.1371/journal.pone.0027560.g007
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